Drug intelligence / Profile preview

BAM8-22

Development stage
Preclinical
Lead developer
Aalborg University Hospital
Modality
Peptides, Small Molecules
Administration
Intradermal, Intrathecal, Subcutaneous
01

Overview

BAM8–22 is a 15-amino acid endogenous peptide fragment derived from proenkephalin A. It acts as a potent and selective agonist for Mas-related G protein-coupled receptors (MRGPRs), specifically human MRGPRX1 and mouse MrgprC11. Unlike related peptides containing the met-enkephalin motif, BAM8–22 does not bind opioid receptors. In preclinical models, it induces scratching behavior in mice via activation of sensory neuron-specific GPCRs and is considered an endogenous pruritogen mediating histamine-independent itch in both mice and humans. Additionally, it has been shown to attenuate bone cancer pain in animal models by modulating mitochondrial function in spinal cord neurons[1][4][5][6][7][10].

Other names
BAM (8-22) acetateBovine adrenal medulla peptide (8-22)L-Valyl-glycyl-L-arginyl-L-prolyl-L-glutamyl-L-tryptophyl-L-tryptophyl-L-methionyl-L-aspartyl-L-tyrosyl-L-glutaminyl-L-lysyl-L-arginyl-L-tyrosyl-glycineVal-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly
02

Targets

MRGPRX1 (Mas-related G protein-coupled receptor X1)MrgprC11 (Mas-related G protein-coupled receptor C11)

Beyond the preview

Go deeper on BAM8-22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAM8-22.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call